Oxygen treatment reduces neurological deficits and demyelination in two animal models of multiple sclerosis.


Journal

Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829

Informations de publication

Date de publication:
02 2023
Historique:
revised: 07 11 2022
received: 22 03 2022
accepted: 11 12 2022
pubmed: 16 12 2022
medline: 3 3 2023
entrez: 15 12 2022
Statut: ppublish

Résumé

The objective of the study is to explore the importance of tissue hypoxia in causing neurological deficits and demyelination in the inflamed CNS, and the value of inspiratory oxygen treatment, using both active and passive experimental autoimmune encephalomyelitis (EAE). Normobaric oxygen treatment was administered to Dark Agouti rats with either active or passive EAE, compared with room air-treated, and naïve, controls. Severe neurological deficits in active EAE were significantly improved after just 1 h of breathing approximately 95% oxygen. The improvement was greater and more persistent when oxygen was applied either prophylactically (from immunisation for 23 days), or therapeutically from the onset of neurological deficits for 24, 48, or 72 h. Therapeutic oxygen for 72 h significantly reduced demyelination and the integrated stress response in oligodendrocytes at the peak of disease, and protected from oligodendrocyte loss, without evidence of increased oxidative damage. T-cell infiltration and cytokine expression in the spinal cord remained similar to that in untreated animals. The severe neurological deficit of animals with passive EAE occurred in conjunction with spinal hypoxia and was significantly reduced by oxygen treatment initiated before their onset. Severe neurological deficits in both active and passive EAE can be caused by hypoxia and reduced by oxygen treatment. Oxygen treatment also reduces demyelination in active EAE, despite the autoimmune origin of the disease.

Identifiants

pubmed: 36520661
doi: 10.1111/nan.12868
pmc: PMC10107096
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12868

Informations de copyright

© 2022 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

Références

J Neurosci Res. 2022 Oct;100(10):1845-1861
pubmed: 35856508
J Neuroradiol. 2017 Mar;44(2):158-164
pubmed: 27865557
Acta Neuropathol. 2014 Aug;128(2):247-66
pubmed: 24622774
Mult Scler Int. 2013;2013:598093
pubmed: 23691321
Acta Neuropathol. 2005 Jan;109(1):49-55
pubmed: 15645261
Cochrane Database Syst Rev. 2004;(1):CD003057
pubmed: 14974004
Acta Neuropathol Commun. 2022 Apr 11;10(1):51
pubmed: 35410629
J Immunol. 2002 Apr 15;168(8):4173-83
pubmed: 11937578
Mult Scler. 1999 Jun;5(3):138-46
pubmed: 10408713
CNS Neurosci Ther. 2010 Apr;16(2):115-24
pubmed: 20415839
Ann Neurol. 2013 Dec;74(6):815-25
pubmed: 24038279
Res Publ Assoc Res Nerv Ment Dis. 1950;28:203-15
pubmed: 15413013
Int J Mol Sci. 2017 Feb 08;18(2):
pubmed: 28208701
Ann Neurol. 2020 Jul;88(1):123-136
pubmed: 32293054
Cell. 2011 Sep 2;146(5):772-84
pubmed: 21871655
Front Neurol. 2018 May 02;9:305
pubmed: 29780351
Sci Rep. 2015 Nov 13;5:16477
pubmed: 26563581
Nat Commun. 2015 Mar 13;6:6532
pubmed: 25766071
Radiology. 2004 Jun;231(3):645-52
pubmed: 15163806
Eur J Neurol. 2022 Aug;29(8):2299-2308
pubmed: 35474598
Ann Neurol. 2016 Apr;79(4):591-604
pubmed: 26814844
Neural Regen Res. 2020 Apr;15(4):646-652
pubmed: 31638086
Biomedicines. 2021 Mar 05;9(3):
pubmed: 33808042
Brain. 1996 Feb;119 ( Pt 1):225-37
pubmed: 8624684
Brain. 2019 Feb 1;142(2):344-361
pubmed: 30657878
Neuroimage. 2006 Dec;33(4):1029-35
pubmed: 16996280
Int Rev Cell Mol Biol. 2017;328:49-103
pubmed: 28069137
Glia. 2022 Nov;70(11):2045-2061
pubmed: 35762739
Mult Scler J Exp Transl Clin. 2021 Jul 29;7(3):20552173211037002
pubmed: 34377529
Brain. 2008 Jan;131(Pt 1):288-303
pubmed: 18056737
Front Neurosci. 2015 Jul 29;9:264
pubmed: 26283904
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Nat Cell Biol. 2011 Mar;13(3):184-90
pubmed: 21364565
Front Neurol. 2020 Jul 17;11:700
pubmed: 32765407
J Neurol Sci. 2003 Feb 15;206(2):187-91
pubmed: 12559509
Transl Neurodegener. 2019 Dec 09;8:37
pubmed: 31827784
Brain Pathol. 1998 Oct;8(4):681-94
pubmed: 9804377
Mult Scler. 2019 Nov;25(13):1715-1718
pubmed: 30052113
Neuropathol Appl Neurobiol. 2023 Feb;49(1):e12868
pubmed: 36520661
Arch Pharm Res. 2020 Oct;43(10):1017-1030
pubmed: 33119885
AJNR Am J Neuroradiol. 2016 Aug;37(8):1454-61
pubmed: 27012299
Mol Cell Biol. 2002 Nov;22(21):7405-16
pubmed: 12370288
Nature. 2016 Jan 21;529(7586):326-35
pubmed: 26791723
Sci Rep. 2016 Sep 14;6:33249
pubmed: 27624721
Eur J Immunol. 1993 Jun;23(6):1364-72
pubmed: 7684687
Int J Mol Sci. 2019 Oct 09;20(20):
pubmed: 31600882
J Cereb Blood Flow Metab. 2015 Sep;35(9):1406-10
pubmed: 26104292
Eur J Biochem. 1998 May 1;253(3):743-50
pubmed: 9654074
Front Cell Dev Biol. 2018 Oct 10;6:132
pubmed: 30364203
Glia. 2001 Nov;36(2):220-34
pubmed: 11596130
Biochem J. 2009 Jan 1;417(1):1-13
pubmed: 19061483
Nat Neurosci. 2009 Apr;12(4):379-85
pubmed: 19287390
Elife. 2021 Feb 10;10:
pubmed: 33565962
J Neurol Neurosurg Psychiatry. 2014 May;85(5):544-51
pubmed: 24039024
Ann Neurol. 2000 Jun;47(6):707-17
pubmed: 10852536
J Neurosci Res. 2004 Jun 15;76(6):822-33
pubmed: 15160394
Science. 2011 Nov 25;334(6059):1081-6
pubmed: 22116877
Acta Neurol Scand. 1995 May;91(5):330-4
pubmed: 7639061
J Neuroimmunol. 2005 Dec 30;170(1-2):71-84
pubmed: 16198426
J Neuropathol Exp Neurol. 2003 Jan;62(1):25-33
pubmed: 12528815
Acta Neuropathol Commun. 2013 Jul 15;1:37
pubmed: 24252779
Nat Med. 2011 Apr;17(4):495-9
pubmed: 21441916
Brain Pathol. 2003 Oct;13(4):554-73
pubmed: 14655760
Eur Neurol. 1993;33(2):163-7
pubmed: 8467826
Clin Sci (Lond). 2017 Oct 12;131(20):2503-2524
pubmed: 29026001
Cancer Res. 1998 Sep 1;58(17):3765-8
pubmed: 9731480
Brain. 2005 May;128(Pt 5):979-87
pubmed: 15774507
Brain. 2021 Mar 3;144(2):402-410
pubmed: 33351069

Auteurs

Mario Amatruda (M)

Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Kate Harris (K)

Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.

Alina Matis (A)

Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.

Andrew L Davies (AL)

Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.

Daniel McElroy (D)

Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, Glasgow Biomedical Research Centre, Glasgow, UK.

Michael Clark (M)

Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.

Christopher Linington (C)

Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, Glasgow Biomedical Research Centre, Glasgow, UK.

Roshni Desai (R)

Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.

Kenneth J Smith (KJ)

Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH